Re-Inventing the Runway - Immersive Exhibition Launch
7.10.2024 02:00:00 CEST | ACCESS Newswire | Press release
Fashion Just Got Hacked - Welcome to the New Runway
LONDON, ENGLAND / ACCESSWIRE / October 7, 2024 / Runway Magazine invites you to the launch of "Re-Inventing the Runway," a groundbreaking immersive exhibition available to everyone, anywhere. This unique exhibition redefines the traditional runway show, transforming it into an interactive, real-time event that engages audiences across all devices - mobile, desktop, and through the Meta Quest 3S headset. Seamlessly accessible through RUNWAYMAGAZINES.com and RUNWAYUNIVERSE.com, this exhibition is not just a glimpse into the world of creativity but a portal to explore, interact, and become part of an evolving narrative.
Re-Inventing the Runway - immersive exhibition
Re-Inventing the Runway - immersive exhibition by RUNWAY MAGAZINE
Beyond the Screen: An Immersive Reality
"Re-Inventing the Runway" merges the world of imagination with cutting-edge technology, creating a living animation where dreams and reality blend seamlessly. The moment you step into this Web3 environment, you are transported to a dynamic world that reshapes how you engage with art, culture, and storytelling. The exhibition goes beyond visuals-it's an interactive journey that brings you directly into the heart of creativity.
Through stunning 3D environments, soundscapes, and interactive elements, audiences don't just observe; they participate. Each visitor becomes a creator, actively exploring a shared space where imagination and technology redefine modern expression. It's an opportunity to experience a new kind of runway show.
Redefining Luxury and Engagement
Historically seen as distant and exclusive, the concept of luxury evolves in this exhibition. Once seen as exclusive and distant, luxury now faces criticism for unsustainable practices and environmental impact. This experience tackles those issues head-on by presenting a new vision for luxury-one that's inclusive, sustainable, and harmonious with nature.
Through enchanting digital landscapes, this exhibition reimagines luxury as a shared experience, allowing visitors to explore a world where creativity, sustainability, and personal expression come together. The immersive environment encourages participants to rethink their understanding of luxury, bringing a deeper sense of connection to artistry and environmental consciousness.
A New Narrative: Gamification of Media
Runway Magazine's Web3 exhibition introduces a new way to experience storytelling, gamifying traditional media and transforming how stories are told. With editorial insights embedded into the virtual world, participants are invited to step into the narrative, turning passive viewing into active engagement. It's not just about consuming content; it's about being part of a creative journey that transforms the traditional runway show into a dynamic, interactive space.
Experience the Future of Creativity
We invite you to explore "Re-Inventing the Runway" - an immersive exhibition that redefines what it means to engage with creativity, luxury, and technology. Become part of a new narrative where every step you take is a new adventure into the future of runway shows and digital experiences, breaking the boundaries of what an exhibition can be.
Welcome to "Re-Inventing the Runway" - where the future of immersive exhibitions is ready for you.
Contact Information
Communication Team
Team
info@runwaymagazines.com
SOURCE: RUNWAY magazine
View the original press release on newswire.com.
RUNWAY magazine
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 20268.4.2026 17:15:00 CEST | Press release
New AI-powered platform establishes an embedded intelligence layer for the AI economy, delivering decision-grade insight BOSTON, MA / ACCESS Newswire / April 8, 2026 / IDC today opened IDC Directions 2026, its flagship client event, bringing together technology leaders, analysts, and industry experts to examine the forces reshaping the global technology market and to introduce a major evolution in how technology intelligence is delivered. At the center of this year's event is IDC Quanta™, a new AI-powered platform that establishes what IDC defines as the technology intelligence layer for the AI economy. As artificial intelligence accelerates the pace of business and compresses decision cycles, IDC is redefining its role from a destination for research and data to an embedded intelligence capability that delivers trusted insight directly into the workflows where decisions are made. "AI is compressing time across the entire technology market, and that breaks the traditional research mode
DistillerSR Launches the Industry's Most Advanced GenAI Capabilities for Extracting Scientific Literature Evidence8.4.2026 16:00:00 CEST | Press release
DistillerSR's Smart Evidence Extraction Now Fully Automates Text and Table Data at Scale OTTAWA, ON / ACCESS Newswire / April 8, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced new fully automated capabilities for its Smart Evidence Extraction (SEE) module. SEE uses purpose-built GenAI to automate end‑to‑end workflows for extracting evidence from scientific literature at scale, while maintaining full auditability and human governance over AI‑generated outputs. As the volume of published research continues to grow exponentially, research teams in the pharmaceutical and medical device industries face increasing pressure to monitor evidence with speed and precision. SEE enables research professionals to accurately find, suggest, explain, extract, and link the supporting evidence within the reference in a human-in-the-loop and fully automated workflow. "The latest version of SEE is designed to move research teams fro
Envision Pharma Group appoints Nick Jones as President, Envision Medical Communications8.4.2026 14:00:00 CEST | Press release
Seasoned technology and life sciences leader to advance AI integration across medical communications FAIRFIELD, CT / ACCESS Newswire / April 8, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, today announced the appointment of Nick Jones as President, Envision Medical Communications (EMC). In this role, Jones will lead the EMC business, focusing on integrating Envision's industry-leading technology and AI capabilities into its award-winning portfolio of solutions and services. Jones joins the company from ConcertAI, where he served as Senior Vice President and General Manager, Commercial Solutions, leading teams delivering consulting services, AI-driven software-as-a-service solutions, and data products supporting pharmaceutical commercialization. Prior to ConcertAI, he spent over a decade at IQVIA (formerly IMS), leading technology and consulting organizations across the US, Europe, and JAPAC, delivering an integra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom